Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVESOR: a Phase 1 Trial of Everolimus and Sorafenib to Assess the Impact of Doses and Administration Sequences on Pharmacokinetic and Pharmacodynamic Effects of the Combination

NCT01932177 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT01932177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01932177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVESOR: a Phase 1 Trial of Everolimus and Sorafenib to Assess the Impact of Doses and Administration Sequences on Pharmacokinetic and Pharmacodynamic Effects of the Combination
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2013
Completion date
October 31, 2015
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or locally advanced solid tumors